Given our result that Apatinib inhibits cellular invasion and migration by fusion kinase KIF5B-RET, it may be possible of using Apatinib in tumors harboring RET gene fusions, especially those with metastatic diseases, which needs further animal studies or clinical trials to confirm. The gene discussed is RET; the disease is metastatic neoplasm.